about
microRNA-146a inhibits G protein-coupled receptor-mediated activation of NF-κB by targeting CARD10 and COPS8 in gastric cancerFOXP1 directly represses transcription of proapoptotic genes and cooperates with NF-κB to promote survival of human B cellsCancer-selective targeting of the NF-κB survival pathway with GADD45β/MKK7 inhibitorsTumor suppressor PDCD4 inhibits NF-κB-dependent transcription in human glioblastoma cells by direct interaction with p65Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphomaThe RNA helicase A in malignant transformationRINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesisNF-κB in cellular senescence and cancer treatmentCutaneous T-cell lymphoma: 2014 update on diagnosis, risk-stratification, and managementDynamic aberrant NF-κB spurs tumorigenesis: a new model encompassing the microenvironmentNovel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive reviewStructural analysis of phenothiazine derivatives as allosteric inhibitors of the MALT1 paracaspaseAnalysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation.Transcription Factors in the Cellular Response to Charged Particle ExposureNF-κB directly regulates Fas transcription to modulate Fas-mediated apoptosis and tumor suppressionOncogenically active MYD88 mutations in human lymphomaRegulation and function of TPL-2, an IκB kinase-regulated MAP kinase kinase kinaseInfluence of caloric restriction on constitutive expression of NF-κB in an experimental mouse astrocytomaChemotherapeutics and radiation stimulate MHC class I expression through elevated interferon-beta signaling in breast cancer cellsA phase I clinical trial of systemically delivered NEMO binding domain peptide in dogs with spontaneous activated B-cell like diffuse large B-cell lymphomaProteomic Signatures of ThymomasInflammation meets cancer, with NF-κB as the matchmakerClustering of CARMA1 through SH3-GUK domain interactions is required for its activation of NF-κB signalling.Oncogenic CARMA1 couples NF-κB and β-catenin signaling in diffuse large B-cell lymphomas.Disruption of IkappaB kinase (IKK)-mediated RelA serine 536 phosphorylation sensitizes human multiple myeloma cells to histone deacetylase (HDAC) inhibitors.High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells.Chromosomal minimal critical regions in therapy-related leukemia appear different from those of de novo leukemia by high-resolution aCGH.How the venom from the ectoparasitoid Wasp nasonia vitripennis exhibits anti-inflammatory properties on mammalian cell lines.Diffuse large B-cell lymphoma: can genomics improve treatment options for a curable cancer?O-GlcNAcylation: The Sweet Side of the Cancer.Transglutaminase regulation of cell function.When less may be more: calorie restriction and response to cancer therapy.IKK is a therapeutic target in KRAS-Induced lung cancer with disrupted p53 activity.TRAF2 is an NF-κB-activating oncogene in epithelial cancers.Chronic inflammation and cancer: potential chemoprevention through nuclear factor kappa B and p53 mutual antagonismDEAD-box helicase DP103 defines metastatic potential of human breast cancers.A review of the application of inflammatory biomarkers in epidemiologic cancer research.Akt-dependent activation of mTORC1 complex involves phosphorylation of mTOR (mammalian target of rapamycin) by IκB kinase α (IKKα).Negative regulation of NF-κB activity by brain-specific TRIpartite Motif protein 9.A critical review of the molecular pathophysiology of lenalidomide sensitivity in 5q - myelodysplastic syndromes.
P2860
Q24299080-9C7A635E-A095-4C29-ABEA-A9BDCEDA7B60Q24304887-96F56D0F-29A7-428E-8D9C-1B5A710F6919Q24305602-C4C44209-9FD6-4159-9B60-93A25578C30AQ24319537-AD10A1CE-2FF8-47F9-919C-684E7DEE9AB6Q24633761-F2AECBD1-E41C-43AC-9C42-AC2CB86B63D7Q26765181-430D6307-BBA4-490A-A8D7-10F3B5ED4C47Q26853207-CCFEEFB9-F6D4-4B9A-B71D-AC7A44CD19FAQ27007045-61BECE02-7898-491E-89D5-3C6CEF0056A7Q27024076-4733E42B-486F-42E6-B5FF-AFEA9B30E84BQ27025321-4A5A4A7B-CCD0-4F7A-B08E-03A050F974CAQ27304386-4CD82DA4-F464-4BCD-9440-E49507B54BD4Q27685382-D9AF80B8-4F19-4631-83BB-0835443E0D3FQ27851655-07EAC51F-360E-4FCE-AA20-3BE6E1434405Q28069717-36FF2804-B8DF-4526-B3B4-B4A596D2CF21Q28268202-4C022FA7-6EB8-4EDD-A1A8-03BF4FB9B640Q28301648-4B323AD0-835D-4002-A51D-6223820ED8AFQ28392677-1C0B6656-548E-4DC8-A118-866861B1C318Q28477560-1DA9B7C2-F425-42BF-A2A1-4826174AD582Q28481351-F969D035-C792-4907-A595-A0A18F9A58ABQ28538467-E0B7FBA4-3617-4A75-A5AA-A82293EDCE76Q28553440-D45217DA-6064-49C4-BA86-459EA4FF51C8Q29620242-94C49258-B395-44B7-AED4-2175C1C76659Q30009245-4DD27D52-1B4F-40C5-AA76-40F0B88E73FCQ30375911-382C0044-BB87-481D-9DB0-A28B741CDC0EQ30424831-689506F2-065A-4DB1-BCB4-06D79B17EB93Q30433183-3F334456-6A70-4A71-A3D7-4B52C426EFCFQ33394269-8EDA864C-8A54-4C60-866C-1AB84AB4F382Q33599721-D3DD7748-C10B-4744-B6D5-971006323700Q33622342-83C3D8D4-DEE4-48BB-9238-2F7CFAFD3DADQ33701447-105FD547-BED4-4409-BA8C-62E1EE7EC640Q33707936-799E1297-1977-4D91-940E-A9BA5335818AQ33721921-412DD819-FF6B-4B10-99C8-0E4458A1F3A7Q33776852-83ECF67E-AFB8-46FB-A44A-9D0F383A50D4Q33794121-B501ED88-56CA-4F67-9E1B-3095B1A4EF57Q34079481-8B6764BA-8DB9-425D-AC6B-D7D27ACFA0BCQ34117601-37ACD288-1F80-4B3A-B7AA-0F62CF11962DQ34135803-97A84D34-913F-4D59-9DA8-C62B3DB21201Q34139142-D5245AF4-566C-4C0C-B1C0-B02790E87E0BQ34147534-E18B327F-EDA4-48C4-9DA7-F4E20C1B5F9FQ34220013-EAA4898D-60F5-45C1-AAEA-9CEE7718D036
P2860
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Oncogenic activation of NF-kappaB.
@ast
Oncogenic activation of NF-kappaB.
@en
type
label
Oncogenic activation of NF-kappaB.
@ast
Oncogenic activation of NF-kappaB.
@en
prefLabel
Oncogenic activation of NF-kappaB.
@ast
Oncogenic activation of NF-kappaB.
@en
P2860
P1476
Oncogenic activation of NF-kappaB.
@en
P2093
Louis M Staudt
P2860
P304
P356
10.1101/CSHPERSPECT.A000109
P577
2010-04-21T00:00:00Z